Reports Q3 revenue EUR 1.52B vs. EUR 1.24B last year. “In the third quarter, we made substantial progress in executing against our oncology strategy. We advanced our priority pan-tumor programs, mRNA cancer immunotherapies and pumitamig. Simultaneously, we further broadened these programs to include evaluation of novel combinations with the aim to deliver differentiated or best-in-class therapeutic profiles,” said Prof. Ugur Sahin, M.D., Chief Executive Officer and Co-Founder of BioNTech (BNTX). “Our collaboration with Bristol Myers Squibb on pumitamig is already demonstrating the strength of this partnership, with multiple additional pivotal trials in preparation with pumitamig planned to start this and next year. This illustrates our commitment to delivering truly transformative options for patients in need.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- BNTX Upcoming Earnings Report: What to Expect?
- BioNTech’s Latest Study on BNT327: A Potential Game-Changer in Lung Cancer Treatment
- Genmab and BioNTech’s Promising Study on Metastatic Colorectal Cancer Treatment
- Bristol-Myers Squibb and BioNTech Launch New Colorectal Cancer Study
- Bristol-Myers Squibb and BioNTech’s New Study: A Potential Game-Changer in Cancer Treatment?